Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of PRJ1-3024 in advanced solid tumors
CTR20220580Phase 2Active
- Sponsor
- Zhuhai Yufan Biotechnology
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of prj1-3024 in Nonhematologic neoplasms, sponsored by Zhuhai Yufan Biotechnology. Started May 2022; status: active.
02
Drugs
prj1-3024
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220580.